title: Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations.
abstract: Ischemic heart disease (IHD) is the leading cause of death worldwide. Novel cardioprotective strategies are therefore required to improve clinical outcomes in patients with IHD. Although a large number of novel cardioprotective strategies have been discovered in the research laboratory, their translation to the clinical setting has been largely disappointing. The reason for this failure can be attributed to a number of factors including the inadequacy of the animal ischemia-reperfusion injury models used in the preclinical cardioprotection studies and the inappropriate design and execution of the clinical cardioprotection studies. This important issue was the main topic of discussion of the UCL-Hatter Cardiovascular Institute 6th International Cardioprotection Workshop, the outcome of which has been published in this article as the "Hatter Workshop Recommendations". These have been proposed to provide guidance on the design and execution of both preclinical and clinical cardioprotection studies in order to facilitate the translation of future novel cardioprotective strategies for patient benefit.
authors.affiliation: The Hatter Cardiovascular Institute, University College London Hospitals and Medical School, 67 Chenies Mews, London, WC1E 6HX, UK.
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Hausenloy
authors.forename: Gary
authors.initials: G
authors.lastname: Baxter
authors.forename: Robert
authors.initials: R
authors.lastname: Bell
authors.forename: Hans Erik
authors.initials: HE
authors.lastname: Bøtker
authors.forename: Sean M
authors.initials: SM
authors.lastname: Davidson
authors.forename: James
authors.initials: J
authors.lastname: Downey
authors.forename: Gerd
authors.initials: G
authors.lastname: Heusch
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kitakaze
authors.forename: Sandrine
authors.initials: S
authors.lastname: Lecour
authors.forename: Robert
authors.initials: R
authors.lastname: Mentzer
authors.forename: Mihaela M
authors.initials: MM
authors.lastname: Mocanu
authors.forename: Michel
authors.initials: M
authors.lastname: Ovize
authors.forename: Rainer
authors.initials: R
authors.lastname: Schulz
authors.forename: Richard
authors.initials: R
authors.lastname: Shannon
authors.forename: Malcolm
authors.initials: M
authors.lastname: Walker
authors.forename: Gail
authors.initials: G
authors.lastname: Walkinshaw
authors.forename: Derek M
authors.initials: DM
authors.lastname: Yellon
mesh_terms: D000367:Age Factors; D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D057775:Ischemic Postconditioning; D019157:Ischemic Preconditioning, Myocardial; D009203:Myocardial Infarction / Q000517:prevention & control*; D017202:Myocardial Ischemia / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D012737:Sex Factors; D013045:Species Specificity; D057170:Translational Research, Biomedical; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents